TITLE

FDA Gout Route Unimpeded, but Will Docs Jump Aboard?

AUTHOR(S)
Osborne, Randy
PUB. DATE
March 2010
SOURCE
BioWorld Insight;3/29/2010, Vol. 18 Issue 13, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers updates on various pharmaceutical companies including Savient Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and BioCryst Pharmaceuticals Inc. New Jersey-based Savient resubmits its biologics license application for Krystexxa in refractory patients. Takeda in Japan encourages rheumatologists and primary-care physicians to accept a new drug in replace of allopurinol. Meanwhile, BioCryst waits the result of the Phase II trials of its nucleoside phosphorylase inhibitor.
ACCESSION #
48966479

 

Related Articles

  • Pharma: Clinic Roundup.  // BioWorld Today;2/22/2012, Vol. 23 Issue 35, p11 

    The article reports on the results of the GEMINI I Phase III trial of vedolizumab conducted by Takeda Pharmaceutical Co. Ltd.

  • Pharma: Clinic Roundup.  // BioWorld Today;5/14/2012, Vol. 23 Issue 93, p6 

    The article focuses on the positive results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal Phase III trial, reported by Takeda Pharmaceuticals Co. Ltd.

  • Takeda's Uloric Continues to Penetrate Moderate to Severe Gout Patients, but Allopurinol Remains Market Share Leader According to Latest BioTrends Report.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article provides information on a report titled "TreatmentTrends(®) Gout," by BioTrends Research Group LLC. According to the report, most surveyed rheumatologists, nephrologists and primary care physicians has cited the increased use of Takeda Pharmaceutical Co. Ltd.'s Uloric in the last...

  • COMPANY SPOTLIGHT - Merck KGaA.  // PharmaWatch: Monthly Review;Nov2005, Vol. 4 Issue 11, p38 

    The article reports that Merck KGaA, under an agreement, has entered into a co-development and co-commercialization with Takeda Pharmaceutical Co. Ltd. for Merck's matuzumab, a humanized monoclonal antibody for the treatment of cancer. Matuzumab was developed by Merck and is in phase II clinical...

  • BIOCRYST COMPLETES BCX-4208 PHASE I TRIAL FOR PSORIASIS.  // Biotech Business;Apr2005, Vol. 18 Issue 4, p8 

    Reports on the completion of the phase one placebo-controlled clinical trials conducted by BioCryst Pharmaceuticals Inc. for its investigational drug BCX-4208 for psoriasis. Plan of the company to evaluate the drug's safety profile and pharmocokinetics in the second quarter of 2005; Statement...

  • CLINIC ROUNDUP.  // BioWorld Today;7/18/2007, Vol. 18 Issue 138, p7 

    This section offers news briefs on the biotechnology and pharmaceutical industries. Avicena Group Inc. will proceed with a confirmatory Phase III trial of AL-02, its lead drug candidate for amyotrophic lateral sclerosis. BioCryst Pharmaceuticals Inc. started first Phase II trial to evaluate...

  • BioCyst begins phase I trial of oral T-cell cancer compound.  // PharmaWatch: Cancer;December2004, Vol. 3 Issue 12, p12 

    Reports that BioCryst Pharmaceuticals Inc. has initiated its phase I trial of anticancer compound, oral forodesine hydrochloride, in refractory patients with cutaneous T-cell lymphoma (CTCL). Objective of the trial to study the pharmacokinetic effects of the drug at 40, 80, 160mg/m2 levels;...

  • Clinic Roundup.  // BioWorld Today;7/25/2012, Vol. 23 Issue 143, p10 

    This section offers news briefs on the pharmaceutical industry. Results of a Phase III trial involving Amarin Corp. plc's AMR101 are available electronically through "The American Journal of Cardiology." BioCryst Pharmaceuticals Inc. has released Phase IIb trial results showing the safety and...

  • BioCryst's Peramivir as Good as Tamiflu.  // Bioworld Week;7/27/2009, Vol. 17 Issue 30, p2 

    The article reports on the result of the Phase III study of the seasonal flu drug peramivir from BioCryst Pharmaceuticals Inc., which proved noninferior to Tamiflu. It notes that the result has encouraged investors for a government stockpiling contract to deal with the invasive threat of swine...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics